October 25, 2021
The Pharmaceuticals and Medical Devices Agency (PMDA) is investigating a new side effect risk of cholangitis sclerosing for Chugai Pharmaceutical’s Tecentriq (atezolizumab), a move likely to trigger a label change in the near future. The PMDA posts its risk communications...read more